// App-Quantinova.ai

360 : Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus

Researchers

Presenter

  • Mark Lazarus

Principal Investigators

  • Paul Newcombe

  • Richard A. Furie

  • Philip Brohawn

  • Wendy White

  • Dominic Sinibaldi

  • Nicola Ferrari

  • Raj Tummala

  • Hussein Al-Mossawi

  • Edward Vital

  • Eric F. Morand

  • Daniel Muthas

  • Madhu Ramaswamy

Medical Centers

  • Astra Zeneca, Cambridge, United Kingdom

  • Northwell Health, Great Neck, NY

  • AstraZeneca, Gaithersburg, MD

  • University of Leeds, Leeds, United Kingdom

  • Deakin University, Melbourne, Australia

  • AstraZeneca, Gothenburg, Sweden

Locations

  • United Kingdom

  • United States

  • Australia

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • MDX1333

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02446912

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved